AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

VTGN · NASDAQ · Biotechnology

VistaGen Therapeutics (VTGN)

Develops intranasal pherine candidates for psychiatric, women's-health, and cancer-supportive-care conditions.

$0.2500

Pre-market+0.00 (+0.64%)

At close$0.2484(+2.10%)

Watchlist

In millions of USD, except per-share figures

In millions	Q2 FY24Sep 2023	Q3 FY24Dec 2023	Q4 FY24Mar 2024	Q1 FY25Jun 2024	Q2 FY25Sep 2024	Q3 FY25Dec 2024	Q4 FY25Mar 2025	Q1 FY26Jun 2025	Q2 FY26Sep 2025	Q3 FY26Dec 2025	Q4 FY26Mar 2026	Q1 FY27Jun 2026
Revenue	0	0	0	0	0	0	0	0	0	0	0	1
Cost of revenue	0	0	0	0	0	0	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0	0	0	0	0	0	1
	7	8	12	12	14	15	14	16	20	20	17	15
Research & development	4	5	7	8	10	11	10	12	16	14	13	11
	3	4	4	5	4	4	4	4	4	5	4	4
General & administrative	3	4	4	5	4	4	4	4	4	5	4	4
Other expenses	0	0	0	0	0	0	0	0	0	0	0	0
Operating income	−7	−8	−11	−12	−14	−15	−14	−16	−20	−20	−17	−13
	0	2	2	1	1	1	1	1	1	1	0	0
Interest income	0	2	2	1	1	1	1	1	1	1	0	0
Other non-operating income	0	0	0	−1	−1	−1	−1	−1	−1	−1	0	0
Income before tax	−7	−6	−10	−11	−13	−14	−14	−15	−19	−19	−16	−13
Income tax expense	0	0	0	0	0	0	0	0	0	0	0	0
Net income from continuing operations	−7	−6	−10	−11	−13	−14	−14	−15	−19	−19	−16	−13
Net income	−7	−6	−10	−11	−13	−14	−14	−15	−19	−19	−16	−13
EPS, basic	−$0.66	−$0.22	−$0.35	−$0.35	−$0.42	−$0.46	−$0.44	−$0.47	−$0.54	−$0.45	−$0.41	−$0.30
EPS, diluted	−$0.66	−$0.22	−$0.35	−$0.35	−$0.42	−$0.46	−$0.44	−$0.47	−$0.54	−$0.45	−$0.41	−$0.30
Weighted average shares, basic	10	29	27	31	31	31	31	32	36	42	40	43
Weighted average shares, diluted	10	29	27	31	31	31	31	32	36	42	40	43
EBITDA	−6	−8	−11	−11	−13	−14	−13	−15	−19	−19	−17	−13
Depreciation & amortization	0	0	0	0	0	0	0	0	0	0	0	0
EBIT	−7	−8	−11	−11	−13	−14	−14	−15	−19	−19	−17	−13